Protein Tyrosine Kinases [electronic resource] : From Inhibitors to Useful Drugs / edited by Doriano Fabbro, Frank McCormick.
| Call Number | 572 |
| Title | Protein Tyrosine Kinases From Inhibitors to Useful Drugs / edited by Doriano Fabbro, Frank McCormick. |
| Physical Description | XIII, 290 p. online resource. |
| Series | Cancer Drug Discovery and Development |
| Contents | Protein Tyrosine Kinases as Targets for Cancer and Other Indications -- Inhibitors of Signaling Interfaces -- PI3-Kinase Inhibition -- Src as a Target for Pharmaceutical Intervention -- Activated FLT3 Receptor Tyrosine Kinase as a Therapeutic Target In Leukemia -- JAK Kinases in Leukemias, Lymphomas, and Multiple Myeloma -- Glivec® (Gleevec®, Imatinib, STI571) -- Platelet-Derived Growth Factor -- Structural Biology of Protein Tyrosine Kinases -- Testing of Signal Transduction Inhibitors in Animal Models of Cancer -- Phosphoproteomics in Drug Discovery and Development. |
| Summary | Protein kinases function as components of signal transduction pathways, playing a central role in the control of cell growth, metabolism, differentiation, and apoptosis. The development of selective protein tyrosine kinase (PTK) inhibitors that can block or modulate diseases, such as cancer, with abnormalities in these signaling pathways is considered a promising approach for drug development. Currently, more than 20 different PTKs are being considered as potential therapeutic targets in oncology. In Protein Tyrosine Kinases: From Inhibitors to Useful Drugs, leading researchers from the Novartis group that pioneered Gleevec/Glivec™ and from around the world comprehensively survey the state-of-the-art in the drug discovery processes (bio- and chemoinformatics, structural biology, profiling, generation of resistance, etc.) aimed at generating PTK inhibitors for the treatment of various diseases, including cancer. Highlights include a discussion of the rationale and the progress made toward generating "selective" low molecular-weight kinase inhibitors; an analysis of the normal function, role in disease, and application of platelet-derived growth factor antagonists; and a summary of the factors involved in successful structure-based drug design. Additional chapters address the advantages and disadvantages of in vivo preclinical models for testing PTK inhibitors with antitumor activity and the utility of different methods in the drug discovery and development process for determining "on-target" vs "off-target" effects of kinase inhibitors. Authoritative and state-of-the-art, Protein Tyrosine Kinases: From Inhibitors to Useful Drugs details the key stages in the design of PTK inhibitors and their development into useful drugs. |
| Added Author | Fabbro, Doriano. editor. McCormick, Frank. editor. SpringerLink (Online service) |
| Subject | LIFE SCIENCES. BIOCHEMISTRY. Life Sciences. Biochemistry, general. |
| Multimedia |
-
Libraries with this item
-
950 BiomedicalandLifeSciences(Springer-11642)
Total Ratings:
0
03877nam a22004815i 4500
001
vtls001568516
003
VRT
005
20170831183700.0
007
cr nn 008mamaa
008
170831s2006 xxu| s |||| 0|eng d
020
$a 9781592599622 $9 978-1-59259-962-2
024
7
$a 10.1385/1592599621 $2 doi
035
$a (DE-He213)978-1-59259-962-2
039
9
$y 201708311837 $z santha
050
4
$a QH345
050
4
$a QD415-436
072
7
$a PSB $2 bicssc
072
7
$a SCI007000 $2 bisacsh
082
0
4
$a 572 $2 23
245
1
0
$a Protein Tyrosine Kinases $h [electronic resource] : $b From Inhibitors to Useful Drugs / $c edited by Doriano Fabbro, Frank McCormick.
264
1
$a Totowa, NJ : $b Humana Press, $c 2006.
300
$a XIII, 290 p. $b online resource.
336
$a text $b txt $2 rdacontent
337
$a computer $b c $2 rdamedia
338
$a online resource $b cr $2 rdacarrier
347
$a text file $b PDF $2 rda
490
1
$a Cancer Drug Discovery and Development
505
0
$a Protein Tyrosine Kinases as Targets for Cancer and Other Indications -- Inhibitors of Signaling Interfaces -- PI3-Kinase Inhibition -- Src as a Target for Pharmaceutical Intervention -- Activated FLT3 Receptor Tyrosine Kinase as a Therapeutic Target In Leukemia -- JAK Kinases in Leukemias, Lymphomas, and Multiple Myeloma -- Glivec® (Gleevec®, Imatinib, STI571) -- Platelet-Derived Growth Factor -- Structural Biology of Protein Tyrosine Kinases -- Testing of Signal Transduction Inhibitors in Animal Models of Cancer -- Phosphoproteomics in Drug Discovery and Development.
520
$a Protein kinases function as components of signal transduction pathways, playing a central role in the control of cell growth, metabolism, differentiation, and apoptosis. The development of selective protein tyrosine kinase (PTK) inhibitors that can block or modulate diseases, such as cancer, with abnormalities in these signaling pathways is considered a promising approach for drug development. Currently, more than 20 different PTKs are being considered as potential therapeutic targets in oncology. In Protein Tyrosine Kinases: From Inhibitors to Useful Drugs, leading researchers from the Novartis group that pioneered Gleevec/Glivec™ and from around the world comprehensively survey the state-of-the-art in the drug discovery processes (bio- and chemoinformatics, structural biology, profiling, generation of resistance, etc.) aimed at generating PTK inhibitors for the treatment of various diseases, including cancer. Highlights include a discussion of the rationale and the progress made toward generating "selective" low molecular-weight kinase inhibitors; an analysis of the normal function, role in disease, and application of platelet-derived growth factor antagonists; and a summary of the factors involved in successful structure-based drug design. Additional chapters address the advantages and disadvantages of in vivo preclinical models for testing PTK inhibitors with antitumor activity and the utility of different methods in the drug discovery and development process for determining "on-target" vs "off-target" effects of kinase inhibitors. Authoritative and state-of-the-art, Protein Tyrosine Kinases: From Inhibitors to Useful Drugs details the key stages in the design of PTK inhibitors and their development into useful drugs.
650
0
$a LIFE SCIENCES.
650
0
$a BIOCHEMISTRY.
650
1
4
$a Life Sciences.
650
2
4
$a Biochemistry, general.
700
1
$a Fabbro, Doriano. $e editor.
700
1
$a McCormick, Frank. $e editor.
710
2
$a SpringerLink (Online service)
773
0
$t Springer eBooks
776
0
8
$i Printed edition: $z 9781588293848
830
0
$a Cancer Drug Discovery and Development
856
4
0
$u http://dx.doi.org/10.1385/1592599621
912
$a ZDB-2-SBL
950
$a Biomedical and Life Sciences (Springer-11642)
999
$a VIRTUA
No Reviews to Display
| Summary | Protein kinases function as components of signal transduction pathways, playing a central role in the control of cell growth, metabolism, differentiation, and apoptosis. The development of selective protein tyrosine kinase (PTK) inhibitors that can block or modulate diseases, such as cancer, with abnormalities in these signaling pathways is considered a promising approach for drug development. Currently, more than 20 different PTKs are being considered as potential therapeutic targets in oncology. In Protein Tyrosine Kinases: From Inhibitors to Useful Drugs, leading researchers from the Novartis group that pioneered Gleevec/Glivec™ and from around the world comprehensively survey the state-of-the-art in the drug discovery processes (bio- and chemoinformatics, structural biology, profiling, generation of resistance, etc.) aimed at generating PTK inhibitors for the treatment of various diseases, including cancer. Highlights include a discussion of the rationale and the progress made toward generating "selective" low molecular-weight kinase inhibitors; an analysis of the normal function, role in disease, and application of platelet-derived growth factor antagonists; and a summary of the factors involved in successful structure-based drug design. Additional chapters address the advantages and disadvantages of in vivo preclinical models for testing PTK inhibitors with antitumor activity and the utility of different methods in the drug discovery and development process for determining "on-target" vs "off-target" effects of kinase inhibitors. Authoritative and state-of-the-art, Protein Tyrosine Kinases: From Inhibitors to Useful Drugs details the key stages in the design of PTK inhibitors and their development into useful drugs. |
| Contents | Protein Tyrosine Kinases as Targets for Cancer and Other Indications -- Inhibitors of Signaling Interfaces -- PI3-Kinase Inhibition -- Src as a Target for Pharmaceutical Intervention -- Activated FLT3 Receptor Tyrosine Kinase as a Therapeutic Target In Leukemia -- JAK Kinases in Leukemias, Lymphomas, and Multiple Myeloma -- Glivec® (Gleevec®, Imatinib, STI571) -- Platelet-Derived Growth Factor -- Structural Biology of Protein Tyrosine Kinases -- Testing of Signal Transduction Inhibitors in Animal Models of Cancer -- Phosphoproteomics in Drug Discovery and Development. |
| Subject | LIFE SCIENCES. BIOCHEMISTRY. Life Sciences. Biochemistry, general. |
| Multimedia |